CD274 and lung carcinoma: The molecular compound NBP target at HBO1 to inhibit the acetylation of H3K14, thereby reducing the enrichment of H3K14ac on the PD‐L1 promoters, blocking the PD‐1 and PD‐L1 signaling axis, and inhibiting the activity and proliferation of lung cancer cells.15